Combination therapy with anti-PD-1, anti-TIM-3, and focal radiation results in regression of murine gliomas

Alessandro Olivi, Antonella Mangraviti, Jennifer E. Kim, Mira A. Patel, Eileen S. Kim, Debebe Theodros, Esteban Velarde, Ann Liu, Eric W. Sankey, Ada Tam, Haiying Xu, Dimitrios Mathios, Christopher M. Jackson, Sarah Harris-Bookman, Tomas Garzon-Muvdi, Mary Sheu, Allison M. Martin, Betty M. Tyler, Phuoc T. Tran, Xiaobu YeJanis M. Taube, Peter C. Burger, Charles G. Drake, Henry Brem, Drew M. Pardoll, Michael Lim

Risultato della ricerca: Contributo in rivistaArticolo in rivista

185 Citazioni (Scopus)


Purpose: Checkpoint molecules like programmed death-1 (PD-1) and T-cell immunoglobulin mucin-3 (TIM-3) are negative immune regulators that may be upregulated in the setting of glioblastoma multiforme. Combined PD-1 blockade and stereotactic radiosurgery (SRS) have been shown to improve antitumor immunity and produce long-term survivors in a murine glioma model. However, tumor-infiltrating lymphocytes (TIL) can express multiple checkpoints, and expression of ≥2 checkpoints corresponds to a more exhausted T-cell phenotype. We investigate TIM-3 expression in a glioma model and the antitumor efficacy of TIM-3 blockade alone and in combination with anti-PD-1 and SRS. Experimental Design: C57BL/6 mice were implanted with murine glioma cell line GL261-luc2 and randomized into 8 treatment arms: (i) control, (ii) SRS, (iii) anti-PD-1 antibody, (iv) anti-TIM-3 antibody, (v) anti-PD-1 + SRS, (vi) anti-TIM-3 + SRS, (vii) anti-PD-1 + anti-TIM-3, and (viii) anti-PD-1 + anti-TIM-3 + SRS. Survival and immune activation were assessed. Results: Dual therapy with anti-TIM-3 antibody + SRS or anti-TIM-3 + anti-PD-1 improved survival compared with anti-TIM-3 antibody alone. Triple therapy resulted in 100% overall survival (P < 0.05), a significant improvement compared with other arms. Long-term survivors demonstrated increased immune cell infiltration and activity and immune memory. Finally, positive staining for TIM-3 was detected in 7 of 8 human GBM samples. Conclusions: This is the first preclinical investigation on the effects of dual PD-1 and TIM-3 blockade with radiation. We also demonstrate the presence of TIM-3 in human glioblastoma multiforme and provide preclinical evidence for a novel treatment combination that can potentially result in long-term glioma survival and constitutes a novel immunotherapeutic strategy for the treatment of glioblastoma multiforme.
Lingua originaleEnglish
pagine (da-a)124-136
Numero di pagine13
RivistaClinical Cancer Research
Stato di pubblicazionePubblicato - 2017


  • Animals
  • Antineoplastic Agents, Immunological
  • Biomarkers
  • Combined Modality Therapy
  • Disease Models, Animal
  • Female
  • Glioma
  • Hepatitis A Virus Cellular Receptor 2
  • Humans
  • Immunologic Memory
  • Immunophenotyping
  • Lymphocytes
  • Lymphocytes, Tumor-Infiltrating
  • Mice
  • Molecular Targeted Therapy
  • Programmed Cell Death 1 Receptor
  • Radiosurgery
  • Survival Analysis
  • Treatment Outcome
  • Tumor Microenvironment


Entra nei temi di ricerca di 'Combination therapy with anti-PD-1, anti-TIM-3, and focal radiation results in regression of murine gliomas'. Insieme formano una fingerprint unica.

Cita questo